Microrna expression analysis: Clinical advantage of propranolol reveals key micrornas in myocardial infarction

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Zhu, Wenliang ^a   Yang, Lei ^b   Shan, Hongli ^c   Zhang, Yong ^c   Zhou, Rui ^a   Su, Zhe ^a   Du, Zhimin ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 29B; MICRORNA 98; PROPRANOLOL; RNA; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FUNCTIONAL PROTEOMICS; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HEART INFARCTION; HEART MUSCLE CELL; MALE; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; RAT; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; VALIDATION STUDY; WISTAR RAT;

RATTUS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MYOCARDIAL INFARCTION; PROPRANOLOL; RATS; RATS, WISTAR; VALIDATION STUDIES AS TOPIC;

EID: 79952225601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014736     Document Type: Article

References (34)

1. Paras KM, Neetu T, Munish K, Suresh CT, (2009) MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 13: 778-789.
2. van Rooij E, Marshall WS, Olson EN, (2008) Toward MicroRNA-Based Therapeutics for Heart Disease. Circ Res 103: 919-928.
3. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, et al. (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348: 7-12.
4. Larsen JA, Kadish AH, Schwartz JB, (2000) Proper use of antiarrhythmic therapy for reduction of mortality after myocardial infarction. Drugs Aging 16: 341-350.
5. Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, et al. (1983) The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67: I26-I32.
6. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T, (1985) Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 5: 1428-1437.
7. Lohse MJ, Engelhardt S, Eschenhagen T, (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93: 896-906.
8. Jackson RJ, Standart N, (2007) How do microRNAs regulate gene expression? Sci STKE 2007 re1.
9. Pan ZW, Lu YJ, Yang BF, (2010) MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta Pharmacol Sin 31: 1-9.
10. Asli NS, Pitulescu ME, Kessel M, (2008) MicroRNAs in Organogenesis and Disease. Curr Mol Med 8: 698-710.
11. Cui Q, Yu Z, Purisima EO, Wang E, (2006) Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol 2: 46.
12. da Silva R, Lucchinetti E, Pasch T, Schaub MC, Zaugg M, (2004) Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol Genomics 20: 117-130.
13. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-416.
14. Naeem H, Küffner R, Csaba G, Zimmer R, (2010) miRSel: automated extraction of associations between microRNAs and genes from the biomedical literature. BMC Bioinformatics 11: 135.
15. Sam GJ, Harpreet KS, Stijn van D, Anton J, (2008) Enright miRBase: tools for microRNA genomics. Nucleic Acids Res 36: 154-158.
16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
17. Yassen A, Fidel R, Sven-Eric S, Thomas L, Mario A, (2008) Computing topological parameters of biological networks. Bioinformatics 24: 282-284.
18. Li F, Li P, Xu W, Peng Y, Bo X, et al. (2010) PerturbationAnalyzer: a tool for investigating the effects of concentration perturbation on protein interaction networks. Bioinformatics 26: 275-277.
19. Arvey A, Larsson E, Sander C, Leslie CS, Marks DS, (2010) Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol 6: 363.
20. Maraziotis IA, Dimitrakopoulou K, Bezerianos A, (2008) An in silico method for detecting overlapping functional modules from composite biological networks. BMC Syst Biol 2: 93.
21. Yu W, Wulf A, Liu T, Khoury MJ, Gwinn M, (2008) Gene Prospector: An evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics 9: 528.
22. Da WH, Brad TS, Richard AL, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
23. Michael VGL, Gianluigi C, (2009) MicroRNAs and cardiac pathology. Nat Rev Cardiol 6: 419-429.
24. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M, (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res 32: D277-D280.
25. Barabási AL, Oltvai ZN, (2004) Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113.
26. Maslov S, Sneppen K, (2002) Specificity and stability in topology of protein networks. Science 296: 910-913.
27. Ghaemmaghami S, Huh WK, Bower K, Howson RW, Belle A, et al. (2003) Global analysis of protein expression in yeast. Nature 425: 737-741.
28. van Rooij E, Olson EN, (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369-2376.
29. Yang B, Lu Y, Wang Z, (2008) Control of cardiac excitability by microRNAs. Cardiovasc Res 79: 571-580.
30. Lu Y, Zhang Y, Shan H, Pan Z, Li X, et al. (2009) MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 84: 434-441.
31. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027-13032.
32. Hu G, Zhou R, Liu J, Gong AY, Eischeid AN, et al. (2009) MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein in response to microbial challenge. J Immunol 183: 1617-1624.
33. Lu Y, Zhang Y, Shan H, Pan Z, Li X, et al. (2009) MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 84: 434-441.
34. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R, (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10: 1507-1517.